SOURCE: Stem Cell Therapy International, Inc.

April 30, 2008 09:17 ET

Stem Cell Therapy International to Present Histostem Merger Opportunity at Investment Banker's Conference May 1 - 3, 2008

TAMPA, FL and SEOUL, SOUTH KOREA--(Marketwire - April 30, 2008) - Calvin Cao, CEO of Stem Cell Therapy International, Inc. (OTCBB: SCII) announced today that he and the newly appointed president, David Stark, will be attending the FSX - Financial Services Exchange (www.fsx1.com/fsx), investment banker's conference in Marina Del Rey, California, May 1 - 3, 2008. The three day event will give Mr. Cao and Mr. Stark an opportunity to meet one-on-one with as many as 40 different investment banking firms and broker-dealers so these leading brokerage and financial services companies can be fully informed with regards to the pending merger between Stem Cell Therapy International and Histostem Co., Ltd. of Korea. David Stark will make the formal speech and slide-show presentation regarding the merger opportunity to all attending conference members on Saturday morning.

About FSX - Financial Services Exchange

Founded in 1983, the FSX conference is for private and public companies seeking mezzanine financing, funding for private placements, IPOs, secondary financing and pipes and exposure. Instead of traveling around the country to meet with individual broker/dealers one at a time, FSX conferences make it possible for representatives of presenting companies to spend several days with key decision makers from firms nationwide. To date, more than $2.8 billion has been raised for presenting companies through the FSX network. FSX has a nationwide network of independent broker/dealers and sponsor organizations. Its member firms have a combined sales force of thousands of licensed professionals. Their clients are looking to invest in companies of all sizes and capabilities.

About Histostem

Histostem, Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and 6 patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. A comprehensive list of Histostem's achievements can be found at the company website http://www.histostem.co.kr (click on English version when entering the site).

About Stem Cell Therapy Int'l, Inc.

Stem Cell Therapy International, Inc. ('SCII') is in the field of regenerative medicine. SCII is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products. Further information about Stem Cell Therapy International, Inc. can be found at its website www.scticorp.com.

Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.

Contact Information

  • For more information, please contact Stem Cell Therapy International, Inc.

    Calvin Cao
    Chairman and CEO
    T: 813-600-4088
    E: calvin@SCTIcorp.com

    Investor Relations:
    Mirador Consulting Inc.
    Frank Benedetto
    T:561-989-3600
    E: fb@miradorconsulting.com